Study of XB010 in Subjects With Solid Tumors
← catalyst calendarNCT06545331 · readout in 96 d
Sponsored by Exelixis (industry) · EXEL — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
396estimated
Sites
20
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-06 | actual | When the study began enrolling |
| Primary completion | 2026-11-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-20 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Locally Advanced or Metastatic Solid Tumors
- Esophageal Squamous Cell Cancer
- Head and Neck Squamous Cell Cancer
- NSCLC (Non-small Cell Lung Cancer)
- Hormone-receptor-positive Breast Cancer
- Triple Negative Breast Cancer (TNBC)
Interventions
- Drug: XB010
- Drug: Pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFDose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010
measured 18 months
Dose-Escalation Stage: Safety of XB010
measured 18 months
Dose-Escalation Stage: Duration of exposure of XB010 [Tolerability]
measured 18 months
Dose-Escalation Stage: Dose intensity of XB010 [Tolerability]
measured 18 months
Cohort-Expansion Stage: Preliminary antitumor activity of XB010
measured 24 months
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed